Rxsight Inc (RXST)
RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacturing, and sale of light adjustable intraocular lenses used in cataract surgery in the United States. Its RxSight system is designed to let ophthalmologists customize a patient’s vision after surgery through the use of a light-adjustable lens and an office-based light delivery device. The lens is made from a photosensitive material that can be modified with programmed ultraviolet light to help achieve the desired visual correction. RxSight was incorporated in 1997, changed its name from Calhoun Vision, Inc. in 2017, and is headquartered in Aliso Viejo, California. The common stock is listed on the NASDAQ under the symbol RXST.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RXST
|
$8
|
46.3% Upside
|
Undervalued
|
$8.43
|
54.1% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-4.9x
|
0.9x
|
1.8x
|
232.2 M
|
22.283 M
|
4.5%
|
94.4%
|
1.5
|
—
|
46.3%
|
